Form 4: Citius Oncology Director Myron Holubiak Receives Stock Options

Myron Holubiak, a director and officer of Citius Oncology, was granted stock options on December 12, 2024.

Summary

• Myron Holubiak, a director and officer of Citius Oncology, received stock options on December 12, 2024.
• He was granted 300,000 options at an exercise price of $1.07, which vest over three years.
• An additional 50,000 options at the same price were granted to his daughter, for which he disclaims beneficial ownership.
• He also holds 1,500,000 options at an exercise price of $2.15, which vest over three years from July 5, 2023.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of stock options to a director and officer aligns their interests with those of the shareholders.
• The vesting schedule of the options encourages long-term commitment from the director.

Risks

• The value of the options is dependent on the future performance of Citius Oncology's stock price.
• The vesting of the options is contingent on the director's continued service to the company.

Future Outlook

The vesting of the options is contingent on the director's continued service to the company.

Industry Context

Stock option grants are a common form of compensation for directors and officers in publicly traded companies, particularly in the biotechnology sector.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedules described are typical, with vesting periods of 1 to 3 years being common.
• The exercise prices are set at or above the market price at the time of grant, which is standard practice.

Related Party Transactions

• The grant of 50,000 stock options to the director's daughter is a related party transaction, although the director disclaims beneficial ownership.

Stakeholder Impact

• The stock option grants may have a positive impact on shareholders by aligning management's interests with the company's long-term success.
• The vesting of the options is contingent on the director's continued service, which benefits the company.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, executive compensation, Citius Oncology, CTOR, Myron Holubiak